

CORRECTION

Open Access



Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study

Frank Tegtmeier¹, Reinhard Schinzel^{1*}, Ronny Beer², Diederik Bulters³, Jean-Yves LeFrant⁴, Joan Sahuquillo⁵, Andreas Unterberg⁶, Peter Andrews⁷, Antonio Belli⁸, Javier Ibanez⁹, Alfonso Lagares¹⁰, Michael Mokry¹¹, Harald Willschke¹², Charlotte Flüh¹³, Erich Schmutzhard² and on behalf of the NOSTRA Investigators

Correction to: *Trials* (2020) 21:80
<https://doi.org/10.1186/s13063-019-3965-4>

After publication of our article [1] the authors have notified us that one of the names has been incorrectly spelled.

- Original name spelling:
Charlotte Flühe
- Correct name spelling:
Charlotte Flüh

The original article has been corrected.

Published online: 12 February 2020

Reference

1. Tegtmeier, et al. Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study. *Trials*. 2020;21:80. <https://doi.org/10.1186/s13063-019-3965-4>.

Author details

¹vasopharm GmbH, Würzburg, Germany. ²Medizinische Universität Innsbruck, Innsbruck, Austria. ³Wessex Neurological Centre University Hospital, Southampton, UK. ⁴Hopital Universitaire Caremeau, Nimes, France. ⁵Vall d'Hebron University Hospital, Barcelona, Spain. ⁶Universitätsklinikum Heidelberg, Heidelberg, Germany. ⁷Western General Hospital Lothian University, Edinburgh, UK. ⁸Queen Elizabeth Hospital, Birmingham, UK. ⁹Espases University Hospital, Palma de Mallorca, Spain. ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain. ¹¹LKH – Universitätsklinikum Graz, Graz, Austria. ¹²Medizinische Universität Wien, Wien, Austria. ¹³Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

The original article can be found online at <https://doi.org/10.1186/s13063-019-3965-4>

* Correspondence: schinzel@vasopharm.de

¹vasopharm GmbH, Würzburg, Germany

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.